Article info
PDFReview Article
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
- Correspondence to Dr Robert L. Coleman, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; rcoleman{at}mdanderson.org
Citation
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
Publication history
- Received March 29, 2019
- Revision received May 1, 2019
- Accepted May 3, 2019
- First published May 22, 2019.
Article Versions
- You are currently viewing a Previous version of this article (2 June 2019).
- View the most recent version of this article
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.